

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Kjell Olmarker)	Group Art Unit: 1652
Application No.: 10/092,919)	Examiner: ROBERT B MONDESI
Filed: March 8, 2002)	Confirmation No.: 1488
For: NOVEL USE OF CYTOKINE INHIBITORS)	

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the listed non-US patent documents is enclosed.

The information is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Continued examination is requested and the fee required under 37 C.F.R. § 1.17(e) was paid herein on September 4, 2007.


To assist the Examiner, the document is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: October 9 2007

By: 
Deborah M. Yellin
Registration No. 45904

P.O. Box 1404
Alexandria, VA 22313-1404
703-836 6620